Archives
-
PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance
2026-09-13
The reference study develops a tumor-microenvironment-responsive nanoparticle system for systemic delivery of PTEN mRNA to trastuzumab-resistant HER2-positive breast cancer. Its central finding is that restoring PTEN expression can suppress persistently active PI3K/Akt signaling, helping re-sensitize resistant tumors to trastuzumab while illustrating the importance of delivery design for therapeutic mRNA.
-
SmCPK24 Links Calcium Signaling to Tanshinones
2026-09-12
This study identifies 25 calcium-dependent protein kinase genes in Salvia miltiorrhiza and shows that SmCPK24 promotes tanshinone accumulation in transgenic hairy roots. Its proposed SmCPK24–SmWRKY1–SmDXS2 module connects calcium signaling with transcriptional control of medicinal diterpenoid biosynthesis.
-
DAMGO Workflows for µ-Opioid Receptor Research
2026-09-11
DAMGO enables selective µ-opioid receptor activation across membrane, tissue, cellular, and pain-circuit experiments. Its value is greatest when researchers pair receptor-level pharmacology with behavioral assays that distinguish analgesia from mechanical hypersensitivity and tolerance.
-
Fenipentol Workflows for GI and CHD Research
2026-09-11
Fenipentol, also called 1-Phenyl-1-pentanol, provides a defined small-molecule tool for connecting volatile Chuanxiong chemistry with secretion, metabolism, and cardiovascular research. This guide translates the reference study into practical assay workflows, controls, optimization steps, and evidence-aware interpretation.
-
Alosetron in Intestinal Signaling Research
2026-09-10
Use Alosetron as a reversible 5-HT3 receptor antagonist to probe serotonin-linked epithelial responses alongside CDC42, YAP/TAZ, Ereg, and mTOR assays. This workflow separates direct receptor pharmacology from polarity-driven intestinal stem cell effects while providing practical controls for DMSO handling, timing, and pathway interpretation.
-
Etoposide (VP-16): From DNA Damage to Delivery
2026-09-10
Etoposide (VP-16) remains a powerful mechanistic probe for topoisomerase II–mediated DNA damage, but its translational value increasingly depends on exposure design, assay integration, and localized delivery. This article connects molecular validation with post-surgical brain tumor strategies.
-
BicD and MAP7 Activate Drosophila Kinesin-1
2026-09-09
The reference study shows that Drosophila BicD and MAP7 activate homodimeric kinesin-1 through complementary mechanisms. BicD relieves kinesin auto-inhibition, whereas full-length MAP7 improves microtubule engagement, producing the strongest motility when both factors are present.
-
GDC-0068: Reading AKT–mTOR Signaling in Context
2026-09-09
GDC-0068 (RG7440) is a selective pan-AKT research inhibitor for connecting pathway blockade with genotype, feedback signaling, and cellular compartment. This article develops an assay-focused framework that distinguishes global AKT pharmacology from spatially restricted mTORC1 biology.
-
Acetylcholine Chloride in Gut–Brain Assays
2026-09-08
Acetylcholine Chloride offers a defined way to interrogate acetylcholine neurotransmitter signaling across gut, vagal, and neuronal preparations. This article translates recent Bacteroides fragilis findings into a causality-focused assay strategy rather than simply repeating the study’s seizure biology.
-
BAPTA: A Causal Tool for Calcium Signaling
2026-09-08
BAPTA is a high-affinity calcium chelator for testing whether intracellular Ca2+ changes drive apoptosis and pathway activation. This article develops a causality-focused assay framework using the IP3R/Ca2+/STAT3 findings in intestinal toxicology while addressing chelator handling, controls, and interpretation.
-
Rosiglitazone for Reliable Cell Assays
2026-09-07
A scenario-driven guide to using Rosiglitazone (SKU A4304) in viability, proliferation, adipogenesis, and metabolic assays. It explains solvent control, stock preparation, data interpretation, and vendor-selection criteria for more defensible PPARγ experiments.
-
Thioredoxin Control of CHK1 Inhibitor Sensitivity
2026-09-07
The 2024 Nature Communications study identifies thioredoxin 1 as a determinant of CHK1 inhibitor response in non-small cell lung cancer. It connects thioredoxin-dependent redox recycling of RRM1 with ribonucleotide reductase activity and deoxynucleotide availability, providing a mechanistic rationale for combining CHK1 and thioredoxin reductase inhibition.
-
Meropenem in Reliable Cell Viability Workflows
2026-09-05
Learn how Meropenem (SKU A5124) can help control bacterial variables in cell viability, proliferation, and infection-model assays. This scenario-based guide connects product specifications with resistance-aware experimental design, solvent control, and interpretation of cytotoxicity data.
-
Protein A/G Magnetic Co-IP/IP Kit for RNF8–DAPK1 Studies
2026-09-04
Translate the RNF8–DAPK1 interaction reported in an ischemic-stroke model into a practical, control-rich Co-IP workflow. Magnetic separation supports rapid protein complex isolation, SDS-PAGE, mass spectrometry, and antibody purification using magnetic beads across compatible biological samples.
-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-09-04
Kartal et al. developed a macrophage-based phenotypic screen to identify small-molecule modulators that reduce SPP1 expression, then incorporated lead compounds into a TAM-avid polymeric nanoconstruct. The lead formulation suppressed SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, establishing a practical framework for targeting tumor-promoting myeloid cells.